Compare VanEck Australian Floating Rate ETF (FLOT) vs Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
VanEck Australian Floating Rate ETF vs Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) — how do they compare? VanEck Australian Floating Rate ETF trades at $50.94 (market cap $11.24B), while Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) trades at $18.63 (market cap $58.74B). The key difference: Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) is far larger — about 5.2× VanEck Australian Floating Rate ETF's market cap, and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) pays a 3.33% dividend while VanEck Australian Floating Rate ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold VanEck Australian Floating Rate ETF for 21 Days and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) for 0 Days on average.
| FLOT | TAK | |
|---|---|---|
Market Cap | $11.24B | $58.74B |
Volume | 1,872,962 | 3,110,994 |
Sector | Fixed Income | Health |
52-Week High | $51.07 | $19.05 |
52-Week Low | $50.72 | $13.23 |
Typical Hold Time | 21 Days | 0 Days |
Enterprise Value | — | $86.65B |
Dividend Yield | — | 3.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLOT trades at $50.91 with minimal daily movement (-0.02%). Technical indicators show a bearish trend with moving averages signaling sell pressure, though oscillators remain neutral. Recent dividend distributions of $0.17-$0.18 highlight income generation. The ETF benefits from floating rate exposure amid Fed tightening cycles, though concentration risk in bank holdings (47% exposure) warrants attention.
Outlook remains tied to interest rate trajectory, with FLOT positioned to benefit from higher rates. Key risks include bank sector concentration and Fed policy shifts. The current technical weakness suggests cautious near-term momentum despite the floating rate advantage in rising rate environments.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About VanEck Australian Floating Rate ETF
FLOT provides exposure to a diversified portfolio of Australian dollar-denominated floating rate notes. It tracks the Bloomberg AusBond Credit FRN 0+ Yr Index, focusing on high-quality, investment-grade bonds from top Australian banks and financial institutions.
Read more on FLOT →About Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)
Takeda is a Japanese pharmaceutical company developing medicines across areas including gastrointestinal disease, rare diseases, neuroscience, oncology, and plasma-derived therapies.
Read more on TAK →
